TY - JOUR
T1 - Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer
AU - Laheru, Daniel
AU - Shah, Preeti
AU - Rajeshkumar, N. V.
AU - McAllister, Florencia
AU - Taylor, Gretchen
AU - Goldsweig, Howard
AU - Le, Dung T.
AU - Donehower, Ross
AU - Jimeno, Antonio
AU - Linden, Sheila
AU - Zhao, Ming
AU - Song, Dongweon
AU - Rudek, Michelle A.
AU - Hidalgo, Manuel
N1 - Funding Information:
Disclaimers: Funding for the study described in this manuscript was provided by Concordia Pharmaceuticals. Concordia Pharmaceuticals is a client of ClinOps, LLC, and Averion International Corp. At the time of the study, Dr. Rudek was a paid consultant to Averion International. The terms of this arrangement were being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
Funding Information:
Supported by: Concordia Pharmaceuticals, Inc. This research was supported by the Analytical Pharmacology Core of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (NIH grants P30 CA006973 and UL1 RR025005). The project described was supported in part by Grant Number UL1 RR 025005 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.
PY - 2012/12
Y1 - 2012/12
N2 - Purpose S-trans,trans-Farnesylthiosalicylic Acid (FTS, salirasib) inhibits Ras-dependent cell growth by dislodging all isoforms of Ras, including mutant Ras, from the plasma membrane. This study evaluated the activity, safety, and toxicity of salirasib in preclinicalmodels and patients with metastatic pancreatic adenocarcinoma (PDA). Patients and methods In the preclinical study, salirasib was tested, alone and in combination with gemcitabine, in patient derived xenografts (PDX) of PDA. In the clinical study, treatment-naïve patients with advanced, metastatic PDA were treated with a standard dose schedule of gemcitabine and salirasib 200-800mg orally (PO) twice daily (bid) for 21 days every 28 days. Tissue from preclinical models and patients' biopsies were collected pre-treatment and on Cycle (C) 1, Day (D) 9 to characterize the effect of gemcitabine and salirasib on activated Ras protein levels. Plasma samples for pharmacokinetics were collected for salirasib administered alone and in combination. Results Salirasib inhibited the growth of 2/14 PDX models of PDA and modulated Ras signaling in these tumors. Nineteen patients were enrolled. No DLTs occurred. Common adverse events included hematologic and gastrointestinal toxicities and fatigue. Themedian overall survival was 6.2months and the 1 year survival 37 %. In 2 patients in whom paired tissue biopsies were available, Ras and KRas protein levels were decreased on C1D9. Salirasib exposure was not altered by gemcitabine and did not correlate with PD outcomes. Conclusion The combination of gemcitabine and salirasib appears well-tolerated, with no alteration of salirasib exposure, and exerted clinical and PD activity in PDA.
AB - Purpose S-trans,trans-Farnesylthiosalicylic Acid (FTS, salirasib) inhibits Ras-dependent cell growth by dislodging all isoforms of Ras, including mutant Ras, from the plasma membrane. This study evaluated the activity, safety, and toxicity of salirasib in preclinicalmodels and patients with metastatic pancreatic adenocarcinoma (PDA). Patients and methods In the preclinical study, salirasib was tested, alone and in combination with gemcitabine, in patient derived xenografts (PDX) of PDA. In the clinical study, treatment-naïve patients with advanced, metastatic PDA were treated with a standard dose schedule of gemcitabine and salirasib 200-800mg orally (PO) twice daily (bid) for 21 days every 28 days. Tissue from preclinical models and patients' biopsies were collected pre-treatment and on Cycle (C) 1, Day (D) 9 to characterize the effect of gemcitabine and salirasib on activated Ras protein levels. Plasma samples for pharmacokinetics were collected for salirasib administered alone and in combination. Results Salirasib inhibited the growth of 2/14 PDX models of PDA and modulated Ras signaling in these tumors. Nineteen patients were enrolled. No DLTs occurred. Common adverse events included hematologic and gastrointestinal toxicities and fatigue. Themedian overall survival was 6.2months and the 1 year survival 37 %. In 2 patients in whom paired tissue biopsies were available, Ras and KRas protein levels were decreased on C1D9. Salirasib exposure was not altered by gemcitabine and did not correlate with PD outcomes. Conclusion The combination of gemcitabine and salirasib appears well-tolerated, with no alteration of salirasib exposure, and exerted clinical and PD activity in PDA.
KW - Gemcitabine
KW - Pancreatic cancer
KW - Phase I
KW - RAS
KW - Salirasib
UR - http://www.scopus.com/inward/record.url?scp=84875534210&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875534210&partnerID=8YFLogxK
U2 - 10.1007/s10637-012-9818-6
DO - 10.1007/s10637-012-9818-6
M3 - Article
C2 - 22547163
AN - SCOPUS:84875534210
SN - 0167-6997
VL - 30
SP - 2391
EP - 2399
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 6
ER -